Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
| Autor: | Herbst, Roy S a, *, Sun, Yan b, Eberhardt, Wilfried EE c, Germonpré, Paul d, Saijo, Nagahiro e, Zhou, Caicun f, Wang, Jie g, Li, Longyun h, Kabbinavar, Fairooz i, Ichinose, Yukito j, Qin, Shukui k, Zhang, Li l, Biesma, Bonne m, Heymach, John V a, Langmuir, Peter n, Kennedy, Sarah J o, Tada, Hiroomi n, Johnson, Bruce E p |
|---|---|
| Zdroj: | In Lancet Oncology 2010 11(7):619-626 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|